Partnership highlights growth in Autoantibody Profiling Sector

Global immunodiagnostics group Oncimmune has signed a partnership with Synexa Life Sciences BV, a provider of biomarker analytical and advisory services in translational and clinical research, that will allow for comprehensive characterisation of the B-cell immune response in a wide range of disease and treatment indications.

Both companies will utilise their expertise to improve patient diagnostics and therapeutics and over the next 18 months Synexa plans to sign multiple new contracts with its partners for autoantibody profiling, that will broaden the business development efforts of Oncimmune’s technology platform.

This new strategic collaboration comes at a time when autoantibody profiling, which provides a depth and breadth of clinical data to improve response and adverse event (irAE) prediction, patient screening and diagnostic accuracy, is experiencing substantial interest, with the market segment growing at approximately 27% year-upon-year.

Dr Adam M Hill, CEO of Oncimmune said: “We welcome this exciting initiative with Synexa Life Sciences, who have recognised the recent progress made by our ImmunoINSIGHTS platform.

The ImmunoINSIGHTS team look forward to the opportunity to deliver high quality, value-adding analysis and interpretation of blood samples for Synexa and its clients, delivering a differentiated service to customers that are yet to engage with our proprietary technology platform.”

More information online